Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)

NCT07503730 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT07503730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07503730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Phase 3
Overall status
Recruiting
Start date
June 1, 2025
Completion date
June 30, 2028
Enrollment
224 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

apl